March 10–11, 2020

2nd BD&L Summit for Life Sciences

Hyatt Centric Fisherman's Warf

San Francisco, CA

REGISTER NOW Group
Graphic 1

Who Attends?

View past participants of our Business Development series.
Group
Graphic 2

Sign Up Today

Register early & save $400 off standard rates.
Group
Graphic 3

Sponsorship

Showcase your technologies, products & services.
Group

WHAT TO EXPECT

In order to effectively evaluate any new business development opportunities and ensure that the true value of a transaction has been realized, while forecasting the probability of both development and commercial success, life science companies need to ensure the right internal experts are involved in the evaluation process. This calls for the development and continuous improvement of a formal process that will allow organizations to efficiently and effectively evaluate, negotiate, manage, and close a transaction.

The 2nd BD&L Summit serves as an open forum for cross-functional business development teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements and M&A deals.

Designed as a platform for M&A, licensing, and transaction executives to share best practices from the biotech and big pharma perspective, this conference goes one step further by providing two tracks dedicated to the following areas:  

  • Legal/Transactions
  • Business Development
VIEW THE AGENDA Group

FEATURED SPEAKERS

KARAH

Karah Parschauer

EVP, General Counsel

ULTRAGENYX

LINUS

Linus S Lin, Ph.D.

Managing Director, Chorus

ELI LILY

CHRIS

Christopher Haskell, Ph.D.

Vice President, Head Open Innovation Center — North America West 

BAYER

JENNIFER

Jennifer Leeds, PH.D.

Executive Director, BD&L

NOVARTIS

OLGA

Olga Kay, J.D., PH.D.

Senior IP Counsel

ROCHE MOLECULAR SOLUTIONS

SHELDON

Sheldon L Koenig, MBA

EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER

PORTOLA PHARMACEUTICALS

PHILIP

Philip Gutry

Chief Business Officer

KRONOS BIO 

JAY

Jay Parish

Chief Business Officer

VIR BIOTECHNOLOGY

EVENT OVERVIEW

Given the complexities of today’s reimbursement landscape, a product’s commercial success is often the most worrying factor. In order to effectively evaluate any new business development opportunities and ensure that every potential for unlocking the value of a transaction has been realized while forecasting the probability of both development and commercial success, life science companies need to ensure the right internal experts are involved in the evaluation process. This calls for the development and continuous improvement of a formal process that will allow organizations to efficiently and effectively evaluate, negotiate, structure, and close a transaction.

The 2nd BD&L Summit for Life Sciences serves as an educational platform for cross-functional experts to share best practices for managing M&A, strategic alliances, and licensing deals, and allows teams to choose their own adventure and tailor their educational experience by attending sessions from two distinct tracks. Don’t miss this opportunity to gain a holistic view of the broader business development process and learn from your peers on how to better support your functional counterparts.

PANEL DISCUSSIONS, TWO TRACKS, AND LEADERSHIP PERSPECTIVES ON TOPICS ESSENTIAL TO YOUR SUCCESS!

  • Explore best practices for companies of all sizes looking to acquire or in-license a product
  • Understand how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal
  • Learn how to evaluate and effectively manage strategic alliances through case studies from industry leaders 
  • Discuss tactics to establish a unique position of leverage during negotiations with multiple parties
  • Gain valuable insight into the impact company culture can have on the success of integrating the workforce post-merger or acquisition

2020 SPONSORS